NCT06535893View on ClinicalTrials.gov

Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2040

Conditions
Breast Cancer
Interventions
DRUG

TN

Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab

DRUG

TN-1

Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC

Trial Locations (1)

467-8601

RECRUITING

Nagoya City University, Nagoya

All Listed Sponsors
collaborator

Japan Clinical Oncology Group

OTHER

lead

Nagoya City University

OTHER